Increased risk of adverse drug reactions by higher linezolid dose per weight in multidrug-resistant tuberculosis

Linezolid treatment has a high risk of toxicity and adverse drug reactions (ADR) are frequent. Few studies have investigated risk factors of major ADRs separately, therefore, we aimed to evaluate major ADRs including peripheral neuropathy in relation to risk factors and drug concentration levels of...

Full description

Saved in:

Bibliographic Details
Published in:	International journal of antimicrobial agents Vol. 64; no. 4; p. 107302
Main Authors:	Kuhlin, Johanna, Davies Forsman, Lina, Osman, Aisha, Skagerberg, Magdalena, Jonsson, Jerker, Groenheit, Ramona, Mansjö, Mikael, Werngren, Jim, Alffenaar, Jan-Willem, Schön, Thomas, Bruchfeld, Judith
Format:	Journal Article
Language:	English
Published:	Netherlands Elsevier Ltd 01.10.2024
Subjects:	adverse drug reactions Anaemia Drug concentrations Infectious Disease Leukopenia Linezolid MDR-TB Peripheral neuropathy Thrombocytopenia Linezolid Thrombocytopenia CTCAE MGIT Leukopenia Anaemia MIC MDR-TB HR Peripheral neuropathy ADR AUC adverse drug reactions Drug concentrations BMI WHO area under the concentration time-curve adverse drug reaction Common Terminology Criteria for Adverse Events World Health Organization body mass index multidrug-resistant tuberculosis minimum inhibitory concentration Mycobacterial Growth Indicator Tube hazard ratio leukopenia linezolid anaemia thrombocytopenia drug concentrations peripheral neuropathy
ISSN:	0924-8579, 1872-7913, 1872-7913
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Abstract	Linezolid treatment has a high risk of toxicity and adverse drug reactions (ADR) are frequent. Few studies have investigated risk factors of major ADRs separately, therefore, we aimed to evaluate major ADRs including peripheral neuropathy in relation to risk factors and drug concentration levels of linezolid in a high-resource setting for multidrug-resistant tuberculosis (MDR-TB). We conducted a retrospective cohort study including participants treated with a linezolid-containing MDR-TB regimen in Sweden 1992–2018. Data was collected from medical records. ADRs were classified according to Common Terminology Criteria for Adverse Events (version 5.0). Of all participants (n = 132), 43.2% were female and the median age 28 y. The median linezolid treatment was 6.5 months (IQR 3.0–12.7) with a median daily dose of 9.6 mg/kg/d. Any ADR was seen in 58.3% (n = 77) of participants, with 35.6% having peripheral neuropathy (n = 47), 27.3% anaemia (n = 36), 22.0% leukopenia (n = 36) while 6.1% (n = 8) had optic neuritis. The median time for peripheral neuropathy was 3.6 months (IQR 2.1–5.9) and 8.3 months (6.2–10.7) for optic neuritis. A >2.0 mg/L trough concentration (n = 40) was associated with anaemia (P = 0.0038) and thrombocytopenia (P = 0.009) but not with peripheral neuropathy. In multivariable analysis, a dose ≥12 mg/kg/d was associated with time to peripheral neuropathy (HR 2.89, 95% CI 1.08–7.74, P = 0.035), anaemia (HR 6.62, 95% CI 2.22–19.8, P = 0.001) and leukopenia (HR 5.23, 95% CI 1.48–18.5, P = 0.010). Linezolid ADRs were frequent in a high-resource setting. Structured, regular follow-up for ADRs and adjusting dosing according to body weight followed-up by monitoring of drug concentrations early may reduce toxicity. [Display omitted]
AbstractList	Linezolid treatment has a high risk of toxicity and adverse drug reactions (ADR) are frequent. Few studies have investigated risk factors of major ADRs separately, therefore, we aimed to evaluate major ADRs including peripheral neuropathy in relation to risk factors and drug concentration levels of linezolid in a high-resource setting for multidrug-resistant tuberculosis (MDR-TB).OBJECTIVESLinezolid treatment has a high risk of toxicity and adverse drug reactions (ADR) are frequent. Few studies have investigated risk factors of major ADRs separately, therefore, we aimed to evaluate major ADRs including peripheral neuropathy in relation to risk factors and drug concentration levels of linezolid in a high-resource setting for multidrug-resistant tuberculosis (MDR-TB).We conducted a retrospective cohort study including participants treated with a linezolid-containing MDR-TB regimen in Sweden 1992-2018. Data was collected from medical records. ADRs were classified according to Common Terminology Criteria for Adverse Events (version 5.0).METHODSWe conducted a retrospective cohort study including participants treated with a linezolid-containing MDR-TB regimen in Sweden 1992-2018. Data was collected from medical records. ADRs were classified according to Common Terminology Criteria for Adverse Events (version 5.0).Of all participants (n = 132), 43.2% were female and the median age 28 y. The median linezolid treatment was 6.5 months (IQR 3.0-12.7) with a median daily dose of 9.6 mg/kg/d. Any ADR was seen in 58.3% (n = 77) of participants, with 35.6% having peripheral neuropathy (n = 47), 27.3% anaemia (n = 36), 22.0% leukopenia (n = 36) while 6.1% (n = 8) had optic neuritis. The median time for peripheral neuropathy was 3.6 months (IQR 2.1-5.9) and 8.3 months (6.2-10.7) for optic neuritis. A >2.0 mg/L trough concentration (n = 40) was associated with anaemia (P = 0.0038) and thrombocytopenia (P = 0.009) but not with peripheral neuropathy. In multivariable analysis, a dose ≥12 mg/kg/d was associated with time to peripheral neuropathy (HR 2.89, 95% CI 1.08-7.74, P = 0.035), anaemia (HR 6.62, 95% CI 2.22-19.8, P = 0.001) and leukopenia (HR 5.23, 95% CI 1.48-18.5, P = 0.010).RESULTSOf all participants (n = 132), 43.2% were female and the median age 28 y. The median linezolid treatment was 6.5 months (IQR 3.0-12.7) with a median daily dose of 9.6 mg/kg/d. Any ADR was seen in 58.3% (n = 77) of participants, with 35.6% having peripheral neuropathy (n = 47), 27.3% anaemia (n = 36), 22.0% leukopenia (n = 36) while 6.1% (n = 8) had optic neuritis. The median time for peripheral neuropathy was 3.6 months (IQR 2.1-5.9) and 8.3 months (6.2-10.7) for optic neuritis. A >2.0 mg/L trough concentration (n = 40) was associated with anaemia (P = 0.0038) and thrombocytopenia (P = 0.009) but not with peripheral neuropathy. In multivariable analysis, a dose ≥12 mg/kg/d was associated with time to peripheral neuropathy (HR 2.89, 95% CI 1.08-7.74, P = 0.035), anaemia (HR 6.62, 95% CI 2.22-19.8, P = 0.001) and leukopenia (HR 5.23, 95% CI 1.48-18.5, P = 0.010).Linezolid ADRs were frequent in a high-resource setting. Structured, regular follow-up for ADRs and adjusting dosing according to body weight followed-up by monitoring of drug concentrations early may reduce toxicity.CONCLUSIONSLinezolid ADRs were frequent in a high-resource setting. Structured, regular follow-up for ADRs and adjusting dosing according to body weight followed-up by monitoring of drug concentrations early may reduce toxicity. Linezolid treatment has a high risk of toxicity and adverse drug reactions (ADR) are frequent. Few studies have investigated risk factors of major ADRs separately, therefore, we aimed to evaluate major ADRs including peripheral neuropathy in relation to risk factors and drug concentration levels of linezolid in a high-resource setting for multidrug-resistant tuberculosis (MDR-TB). We conducted a retrospective cohort study including participants treated with a linezolid-containing MDR-TB regimen in Sweden 1992–2018. Data was collected from medical records. ADRs were classified according to Common Terminology Criteria for Adverse Events (version 5.0). Of all participants (n = 132), 43.2% were female and the median age 28 y. The median linezolid treatment was 6.5 months (IQR 3.0–12.7) with a median daily dose of 9.6 mg/kg/d. Any ADR was seen in 58.3% (n = 77) of participants, with 35.6% having peripheral neuropathy (n = 47), 27.3% anaemia (n = 36), 22.0% leukopenia (n = 36) while 6.1% (n = 8) had optic neuritis. The median time for peripheral neuropathy was 3.6 months (IQR 2.1–5.9) and 8.3 months (6.2–10.7) for optic neuritis. A >2.0 mg/L trough concentration (n = 40) was associated with anaemia (P = 0.0038) and thrombocytopenia (P = 0.009) but not with peripheral neuropathy. In multivariable analysis, a dose ≥12 mg/kg/d was associated with time to peripheral neuropathy (HR 2.89, 95% CI 1.08–7.74, P = 0.035), anaemia (HR 6.62, 95% CI 2.22–19.8, P = 0.001) and leukopenia (HR 5.23, 95% CI 1.48–18.5, P = 0.010). Linezolid ADRs were frequent in a high-resource setting. Structured, regular follow-up for ADRs and adjusting dosing according to body weight followed-up by monitoring of drug concentrations early may reduce toxicity. [Display omitted] Objectives: Linezolid treatment has a high risk of toxicity and adverse drug reactions (ADR) are frequent. Few studies have investigated risk factors of major ADRs separately, therefore, we aimed to evaluate major ADRs including peripheral neuropathy in relation to risk factors and drug concentration levels of linezolid in a high-resource setting for multidrug-resistant tuberculosis (MDR-TB). Methods: We conducted a retrospective cohort study including participants treated with a linezolid-containing MDR-TB regimen in Sweden 1992-2018. Data was collected from medical records. ADRs were classified according to Common Terminology Criteria for Adverse Events (version 5.0). Results: Of all participants (n = 132), 43.2% were female and the median age 28 y. The median linezolid treatment was 6.5 months (IQR 3.0-12.7) with a median daily dose of 9.6 mg/kg/d. Any ADR was seen in 58.3% (n = 77) of participants, with 35.6% having peripheral neuropathy (n = 47), 27.3% anaemia (n = 36), 22.0% leukopenia (n = 36) while 6.1% (n = 8) had optic neuritis. The median time for peripheral neuropathy was 3.6 months (IQR 2.1-5.9) and 8.3 months (6.2-10.7) for optic neuritis. A &gt;2.0 mg/L trough concentration (n = 40) was associated with anaemia (P = 0.0038) and thrombocytopenia (P = 0.009) but not with peripheral neuropathy. In multivariable analysis, a dose &gt;= 12 mg/kg/d was associated with time to peripheral neuropathy (HR 2.89, 95% CI 1.08-7.74, P = 0.035), anaemia (HR 6.62, 95% CI 2.22-19.8, P = 0.001) and leukopenia (HR 5.23, 95% CI 1.48-18.5, P = 0.010). Conclusions: Linezolid ADRs were frequent in a high-resource setting. Structured, regular follow-up for ADRs and adjusting dosing according to body weight followed-up by monitoring of drug concentrations early may reduce toxicity. (c) 2024 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY license ( http://creativecommons.org/licenses/by/4.0/ ) Linezolid treatment has a high risk of toxicity and adverse drug reactions (ADR) are frequent. Few studies have investigated risk factors of major ADRs separately, therefore, we aimed to evaluate major ADRs including peripheral neuropathy in relation to risk factors and drug concentration levels of linezolid in a high-resource setting for multidrug-resistant tuberculosis (MDR-TB). We conducted a retrospective cohort study including participants treated with a linezolid-containing MDR-TB regimen in Sweden 1992-2018. Data was collected from medical records. ADRs were classified according to Common Terminology Criteria for Adverse Events (version 5.0). Of all participants (n=132), 43.2% were female and the median age 28 years. The median linezolid treatment was 6.5 months (IQR 3.0-12.7) with a median daily dose of 9.6 mg/kg/day. Any ADR was seen in 58.3% (n=77) of participants, with 35.6% having peripheral neuropathy (n=47), 27.3% anaemia (n=36), 22.0% leukopenia (n=36) while 6.1% (n=8) had optic neuritis. The median time for peripheral neuropathy was 3.6 months (IQR 2.1-5.9) and 8.3 months (6.2-10.7) for optic neuritis. A >2.0 mg/L trough concentration (n=40) was associated with anaemia (p=0.0038) and thrombocytopenia (p=0.009) but not with peripheral neuropathy. In multivariable analysis, a dose ≥12 mg/kg/day was associated with time to peripheral neuropathy (HR 2.89, 95%CI 1.08-7.74, p=0.035), anaemia (HR 6.62, 95%CI 2.22-19.8, p=0.001) and leukopenia (HR 5.23, 95% CI 1.48-18.5, p=0.010). Linezolid ADRs were frequent in a high-resource setting. Structured, regular follow-up for ADRs and adjusting dosing according to body weight followed-up by monitoring of drug concentrations early may reduce toxicity. AbstractObjectivesLinezolid treatment has a high risk of toxicity and adverse drug reactions (ADR) are frequent. Few studies have investigated risk factors of major ADRs separately, therefore, we aimed to evaluate major ADRs including peripheral neuropathy in relation to risk factors and drug concentration levels of linezolid in a high-resource setting for multidrug-resistant tuberculosis (MDR-TB). MethodsWe conducted a retrospective cohort study including participants treated with a linezolid-containing MDR-TB regimen in Sweden 1992–2018. Data was collected from medical records. ADRs were classified according to Common Terminology Criteria for Adverse Events (version 5.0). ResultsOf all participants (n = 132), 43.2% were female and the median age 28 y. The median linezolid treatment was 6.5 months (IQR 3.0–12.7) with a median daily dose of 9.6 mg/kg/d. Any ADR was seen in 58.3% (n = 77) of participants, with 35.6% having peripheral neuropathy (n = 47), 27.3% anaemia (n = 36), 22.0% leukopenia (n = 36) while 6.1% (n = 8) had optic neuritis. The median time for peripheral neuropathy was 3.6 months (IQR 2.1–5.9) and 8.3 months (6.2–10.7) for optic neuritis. A >2.0 mg/L trough concentration (n = 40) was associated with anaemia ( P = 0.0038) and thrombocytopenia ( P = 0.009) but not with peripheral neuropathy. In multivariable analysis, a dose ≥12 mg/kg/d was associated with time to peripheral neuropathy (HR 2.89, 95% CI 1.08–7.74, P = 0.035), anaemia (HR 6.62, 95% CI 2.22–19.8, P = 0.001) and leukopenia (HR 5.23, 95% CI 1.48–18.5, P = 0.010). ConclusionsLinezolid ADRs were frequent in a high-resource setting. Structured, regular follow-up for ADRs and adjusting dosing according to body weight followed-up by monitoring of drug concentrations early may reduce toxicity.
ArticleNumber	107302
Author	Mansjö, Mikael Werngren, Jim Groenheit, Ramona Kuhlin, Johanna Schön, Thomas Davies Forsman, Lina Skagerberg, Magdalena Alffenaar, Jan-Willem Bruchfeld, Judith Jonsson, Jerker Osman, Aisha
Author_xml	– sequence: 1 givenname: Johanna orcidid: 0000-0002-3398-2421 surname: Kuhlin fullname: Kuhlin, Johanna email: Johanna.kuhlin@ki.se organization: Department of Medicine, Division of Infectious Diseases, Karolinska Institutet, Solna, Sweden – sequence: 2 givenname: Lina surname: Davies Forsman fullname: Davies Forsman, Lina organization: Department of Medicine, Division of Infectious Diseases, Karolinska Institutet, Solna, Sweden – sequence: 3 givenname: Aisha surname: Osman fullname: Osman, Aisha organization: Department of Medicine, Division of Infectious Diseases, Karolinska Institutet, Solna, Sweden – sequence: 4 givenname: Magdalena surname: Skagerberg fullname: Skagerberg, Magdalena organization: Department of Infectious Diseases, Karolinska University Hospital, Stockholm, Sweden – sequence: 5 givenname: Jerker surname: Jonsson fullname: Jonsson, Jerker organization: Department of Public Health Analysis and Data Management, Public Health Agency of Sweden, Stockholm, Sweden – sequence: 6 givenname: Ramona orcidid: 0000-0003-2696-437X surname: Groenheit fullname: Groenheit, Ramona organization: Department of Microbiology, Public Health Agency of Sweden, Stockholm, Sweden – sequence: 7 givenname: Mikael surname: Mansjö fullname: Mansjö, Mikael organization: Department of Microbiology, Public Health Agency of Sweden, Stockholm, Sweden – sequence: 8 givenname: Jim surname: Werngren fullname: Werngren, Jim organization: Department of Microbiology, Public Health Agency of Sweden, Stockholm, Sweden – sequence: 9 givenname: Jan-Willem orcidid: 0000-0001-6703-0288 surname: Alffenaar fullname: Alffenaar, Jan-Willem organization: Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia – sequence: 10 givenname: Thomas surname: Schön fullname: Schön, Thomas organization: Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden – sequence: 11 givenname: Judith surname: Bruchfeld fullname: Bruchfeld, Judith organization: Department of Medicine, Division of Infectious Diseases, Karolinska Institutet, Solna, Sweden
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/39146999$$D View this record in MEDLINE/PubMed https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-207970$$DView record from Swedish Publication Index (Linköpings universitet)
BookMark	eNqNkltrGzEQhZeS0jhp_0JR3_qyji7r1eqlxTi9BAJ96OVVaKVZZ5z1ypW0Ce6vrxYnoQQKfhLMnPk0nDNnxcngByiKd4zOGWX1xWaOGzMk3KI16zmnvMp1KSh_UcxYI3kpFRMnxYwqXpXNQqrT4izGDaVsIarFq-JUKFbVSqlZsbsabAATwZGA8Zb4jhh3ByECcWFck9yzCf0QSbsnN7i-gUB6HOCP79ER57Nul0v3kFuJ4EC2Y59wGi0DRIwp70nS2EKwY-9z4XXxsjN9hDcP73nx8_OnH6uv5fW3L1er5XVpayZT2TnqDLWs46qVyjJKQRrrTC1F4zporINFKwXQjnbCOsubzpiG1kbUDTNMivOiPHDjPezGVu8Cbk3Ya29QX-KvpfZhrXscNadSSZr17w_6XfC_R4hJbzFa6HszgB-jFlSJhaoaOaHfPkjHdgvuCf3oahZ8PAhs8DEG6LTFZCYbUzDYa0b1lKPe6H9y1FOO-pBjJqhnhMdPjpldHWYh23uHEHS0CIMFhwFs0s7jUZQPzyg2555l_S3sIW78GIacn2Y6ck319-nWplPjFaWcNU0GLP8POHKJv5HM7a0
CitedBy_id	crossref_primary_10_1111_bcp_16278 crossref_primary_10_1080_14787210_2025_2506777 crossref_primary_10_1097_FTD_0000000000001343 crossref_primary_10_1186_s12879_025_11491_4 crossref_primary_10_1002_sscp_70051 crossref_primary_10_1097_WCO_0000000000001358
Cites_doi	10.1093/cid/ciac485 10.1093/cid/ciad653 10.1186/s12941-016-0156-y 10.2165/00002018-199410020-00001 10.1097/FTD.0000000000000710 10.1128/AAC.40.4.839 10.1016/j.ebiom.2015.09.051 10.1183/09031936.00035114 10.1016/S2213-2600(20)30047-3 10.1093/jac/dkac019 10.3201/eid2608.191499 10.1016/j.ijantimicag.2017.01.017 10.3389/fphar.2017.00086
ContentType	Journal Article
Copyright	2024 The Author(s) The Author(s) Copyright © 2024. Published by Elsevier Ltd. Copyright © 2024 The Author(s). Published by Elsevier Ltd.. All rights reserved.
Copyright_xml	– notice: 2024 The Author(s) – notice: The Author(s) – notice: Copyright © 2024. Published by Elsevier Ltd. – notice: Copyright © 2024 The Author(s). Published by Elsevier Ltd.. All rights reserved.
DBID	6I. AAFTH AAYXX CITATION NPM 7X8 ABXSW ADTPV AOWAS D8T DG8 ZZAVC
DOI	10.1016/j.ijantimicag.2024.107302
DatabaseName	ScienceDirect Open Access Titles Elsevier:ScienceDirect:Open Access CrossRef PubMed MEDLINE - Academic SWEPUB Linköpings universitet full text SwePub SwePub Articles SWEPUB Freely available online SWEPUB Linköpings universitet SwePub Articles full text
DatabaseTitle	CrossRef PubMed MEDLINE - Academic
DatabaseTitleList	MEDLINE - Academic PubMed
Database_xml	– sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database
DeliveryMethod	fulltext_linktorsrc
Discipline	Biology Pharmacy, Therapeutics, & Pharmacology
EISSN	1872-7913
EndPage	107302
ExternalDocumentID	oai_DiVA_org_liu_207970 39146999 10_1016_j_ijantimicag_2024_107302 S0924857924002188 1_s2_0_S0924857924002188
Genre	Journal Article
GroupedDBID	--- --K --M .1- .FO .GJ .~1 0R~ 1B1 1P~ 1RT 1~. 1~5 29J 4.4 457 4G. 53G 5GY 5VS 7-5 71M 8P~ 9JM AAAJQ AABNK AAEDT AAEDW AAHBH AAIKJ AAKOC AALRI AAOAW AAQFI AAQXK AARKO AATTM AAXKI AAXUO AAYWO ABBQC ABFNM ABFRF ABJNI ABMAC ABMZM ABWVN ABXDB ACDAQ ACGFO ACGFS ACIEU ACIUM ACLOT ACRLP ACRPL ACVFH ADBBV ADCNI ADEZE ADMUD ADNMO ADVLN AEBSH AEFWE AEIPS AEKER AENEX AEUPX AEVXI AFJKZ AFPUW AFRHN AFTJW AFXIZ AGEKW AGHFR AGQPQ AGUBO AGYEJ AHHHB AIEXJ AIGII AIIUN AIKHN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ ANKPU ANZVX APXCP ASPBG AVWKF AXJTR AZFZN BKOJK BLXMC BNPGV CJTIS CNWQP CS3 DU5 EBS EFJIC EFKBS EFLBG EJD EO8 EO9 EP2 EP3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN G-2 G-Q GBLVA HEJ HMG HMK HMO HVGLF HX~ HZ~ IHE J1W KOM LUGTX M29 M41 MO0 N9A O-L O9- OAUVE OD- OO. OZT P-8 P-9 P2P PC. Q38 R2- ROL RPZ SAE SCC SDF SDG SDP SEL SES SEW SIN SPCBC SSH SSI SSZ T5K UNMZH WUQ XPP Z5R ~G- ~HD AACTN AFCTW AFKWA AJOXV AMFUW RIG 6I. AAFTH 9DU AAYXX CITATION AGCQF AGRNS NPM 7X8 ABXSW ADTPV AOWAS D8T DG8 ZZAVC
ID	FETCH-LOGICAL-c617t-fd0da0c1f29b79c100e7acda6738dfe8cde5b73e0f0f3cdc28faa806a3681a173
ISICitedReferencesCount	6
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=001309786300001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	0924-8579 1872-7913
IngestDate	Thu Nov 27 02:50:47 EST 2025 Wed Oct 01 13:45:47 EDT 2025 Mon Jul 21 06:05:01 EDT 2025 Tue Nov 18 21:57:31 EST 2025 Sat Nov 29 01:54:18 EST 2025 Sat Oct 05 15:37:05 EDT 2024 Tue Feb 25 19:57:43 EST 2025 Tue Oct 14 19:27:54 EDT 2025
IsDoiOpenAccess	true
IsOpenAccess	true
IsPeerReviewed	true
IsScholarly	true
Issue	4
Keywords	Linezolid Thrombocytopenia CTCAE MGIT Leukopenia Anaemia MIC MDR-TB HR Peripheral neuropathy ADR AUC adverse drug reactions Drug concentrations BMI WHO area under the concentration time-curve adverse drug reaction Common Terminology Criteria for Adverse Events World Health Organization body mass index multidrug-resistant tuberculosis minimum inhibitory concentration Mycobacterial Growth Indicator Tube hazard ratio leukopenia linezolid anaemia thrombocytopenia drug concentrations peripheral neuropathy
Language	English
License	This is an open access article under the CC BY license. Copyright © 2024. Published by Elsevier Ltd.
LinkModel	OpenURL
MergedId	FETCHMERGED-LOGICAL-c617t-fd0da0c1f29b79c100e7acda6738dfe8cde5b73e0f0f3cdc28faa806a3681a173
Notes	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
ORCID	0000-0003-2696-437X 0000-0002-3398-2421 0000-0001-6703-0288
OpenAccessLink	https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-207970
PMID	39146999
PQID	3093594877
PQPubID	23479
PageCount	1
ParticipantIDs	swepub_primary_oai_DiVA_org_liu_207970 proquest_miscellaneous_3093594877 pubmed_primary_39146999 crossref_citationtrail_10_1016_j_ijantimicag_2024_107302 crossref_primary_10_1016_j_ijantimicag_2024_107302 elsevier_sciencedirect_doi_10_1016_j_ijantimicag_2024_107302 elsevier_clinicalkeyesjournals_1_s2_0_S0924857924002188 elsevier_clinicalkey_doi_10_1016_j_ijantimicag_2024_107302
PublicationCentury	2000
PublicationDate	2024-10-01
PublicationDateYYYYMMDD	2024-10-01
PublicationDate_xml	– month: 10 year: 2024 text: 2024-10-01 day: 01
PublicationDecade	2020
PublicationPlace	Netherlands
PublicationPlace_xml	– name: Netherlands
PublicationTitle	International journal of antimicrobial agents
PublicationTitleAlternate	Int J Antimicrob Agents
PublicationYear	2024
Publisher	Elsevier Ltd
Publisher_xml	– name: Elsevier Ltd
References	Jaspard, Butel, El Helali, Marigot-Outtandy, Guillot, Peytavin (bib0003) 2020; 26 Hasan, Medcalf, Nyang'wa, Egizi, Berry, Dodd (bib0005) 2024; 78 Zurenko, Yagi, Schaadt, Allison, Kilburn, Glickman (bib0012) 1996; 40 Lan, Ahmad, Baghaei, Barkane, Benedetti, Brode (bib0004) 2020; 8 Kerckhove, Collin, Conde, Chaleteix, Pezet, Balayssac (bib0018) 2017; 8 Kamp, Bolhuis, Tiberi, Akkerman, Centis, de Lange (bib0011) 2017; 49 (bib0009) 2013 Edwards, Biriell (bib0013) 1994; 10 Wasserman, Brust, Abdelwahab, Little, Denti, Wiesner (bib0015) 2022; 77 Eimer, Frechet-Jachym, Le Du, Caumes, El-Helali, Marigot-Outtandy (bib0016) 2023; 76 Rao, Konicki, Cattaneo, Alffenaar, Marriott, Neely (bib0019) 2020; 42 (bib0010) 2022; 60 Zhang, Falagas, Vardakas, Wang, Qin, Wang (bib0001) 2015; 7 (bib0006) 2019 (bib0007) 2022 Tang, Yao, Hao, Zhang, Liu, Liu (bib0017) 2015; 45 Song, Lee, Jeon, Park, Dodd, Dartois (bib0014) 2015; 2 Agyeman, Ofori-Asenso (bib0002) 2016; 15 Laserson, Thorpe, Leimane, Weyer, Mitnick, Riekstina (bib0008) 2005; 9 (10.1016/j.ijantimicag.2024.107302_bib0006) 2019 Laserson (10.1016/j.ijantimicag.2024.107302_bib0008) 2005; 9 Eimer (10.1016/j.ijantimicag.2024.107302_bib0016) 2023; 76 Tang (10.1016/j.ijantimicag.2024.107302_bib0017) 2015; 45 Zhang (10.1016/j.ijantimicag.2024.107302_bib0001) 2015; 7 Jaspard (10.1016/j.ijantimicag.2024.107302_bib0003) 2020; 26 (10.1016/j.ijantimicag.2024.107302_bib0009) 2013 Kamp (10.1016/j.ijantimicag.2024.107302_bib0011) 2017; 49 Lan (10.1016/j.ijantimicag.2024.107302_bib0004) 2020; 8 (10.1016/j.ijantimicag.2024.107302_bib0007) 2022 Zurenko (10.1016/j.ijantimicag.2024.107302_bib0012) 1996; 40 Hasan (10.1016/j.ijantimicag.2024.107302_bib0005) 2024; 78 Edwards (10.1016/j.ijantimicag.2024.107302_bib0013) 1994; 10 Song (10.1016/j.ijantimicag.2024.107302_bib0014) 2015; 2 (10.1016/j.ijantimicag.2024.107302_bib0010) 2022; 60 Kerckhove (10.1016/j.ijantimicag.2024.107302_bib0018) 2017; 8 Wasserman (10.1016/j.ijantimicag.2024.107302_bib0015) 2022; 77 Agyeman (10.1016/j.ijantimicag.2024.107302_bib0002) 2016; 15 Rao (10.1016/j.ijantimicag.2024.107302_bib0019) 2020; 42
References_xml	– volume: 26 start-page: 1792 year: 2020 end-page: 1800 ident: bib0003 article-title: Linezolid-associated neurologic adverse events in patients with multidrug-resistant tuberculosis publication-title: France. Emerg Infect Dis. – year: 2019 ident: bib0006 article-title: WHO consolidated guidelines on drug-resistant tuberculosis treatment – volume: 45 start-page: 161 year: 2015 end-page: 170 ident: bib0017 article-title: Efficacy, safety and tolerability of linezolid for the treatment of XDR-TB: a study in China publication-title: Eur Respir J – volume: 8 start-page: 86 year: 2017 ident: bib0018 article-title: Long-term effects, pathophysiological mechanisms, and risk factors of chemotherapy-induced peripheral neuropathies: a comprehensive literature review publication-title: Front Pharmacol – volume: 9 start-page: 640 year: 2005 end-page: 645 ident: bib0008 article-title: Speaking the same language: treatment outcome definitions for multidrug-resistant tuberculosis publication-title: Int J Tuberc Lung Dis – year: 2013 ident: bib0009 article-title: Definitions and reporting framework for tuberculosis–2013 revision – volume: 40 start-page: 839 year: 1996 end-page: 845 ident: bib0012 article-title: In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents publication-title: Antimicrob Agents Chemother – volume: 77 start-page: 1146 year: 2022 end-page: 1154 ident: bib0015 article-title: Linezolid toxicity in patients with drug-resistant tuberculosis: a prospective cohort study publication-title: J Antimicrob Chemother – volume: 8 start-page: 383 year: 2020 end-page: 394 ident: bib0004 article-title: Drug-associated adverse events in the treatment of multidrug-resistant tuberculosis: an individual patient data meta-analysis publication-title: Lancet Respir Med – volume: 2 start-page: 1627 year: 2015 end-page: 1633 ident: bib0014 article-title: Linezolid trough concentrations correlate with mitochondrial toxicity-related adverse events in the treatment of chronic extensively drug-resistant tuberculosis publication-title: EBioMedicine – volume: 42 start-page: 83 year: 2020 end-page: 92 ident: bib0019 article-title: Therapeutic drug monitoring can improve linezolid dosing regimens in current clinical practice: a review of linezolid pharmacokinetics and pharmacodynamics publication-title: Ther Drug Monit – volume: 49 start-page: 688 year: 2017 end-page: 694 ident: bib0011 article-title: Simple strategy to assess linezolid exposure in patients with multi-drug-resistant and extensively-drug-resistant tuberculosis publication-title: Int J Antimicrob Agents – year: 2022 ident: bib0007 article-title: WHO operational handbook on tuberculosis. Module 4: treatment - drug-resistant tuberculosis treatment, 2022 update – volume: 60 year: 2022 ident: bib0010 article-title: Epidemiological cut-off values for a 96-well broth microdilution plate for high-throughput research antibiotic susceptibility testing of M. tuberculosis publication-title: Eur Respir J – volume: 10 start-page: 93 year: 1994 end-page: 102 ident: bib0013 article-title: Harmonisation in pharmacovigilance publication-title: Drug Saf – volume: 78 start-page: 730 year: 2024 end-page: 741 ident: bib0005 article-title: The safety and tolerability of linezolid in novel short-course regimens containing bedaquiline, pretomanid, and linezolid to treat rifampicin-resistant tuberculosis: an individual patient data meta-analysis publication-title: Clin Infect Dis – volume: 15 start-page: 41 year: 2016 ident: bib0002 article-title: Efficacy and safety profile of linezolid in the treatment of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis: a systematic review and meta-analysis publication-title: Ann Clin Microbiol Antimicrob – volume: 76 year: 2023 ident: bib0016 article-title: Association between increased linezolid plasma concentrations and the development of severe toxicity in multidrug-resistant tuberculosis treatment publication-title: Clin Infect Dis – volume: 7 start-page: 603 year: 2015 end-page: 615 ident: bib0001 article-title: Systematic review and meta-analysis of the efficacy and safety of therapy with linezolid containing regimens in the treatment of multidrug-resistant and extensively drug-resistant tuberculosis publication-title: J Thorac Dis – year: 2019 ident: 10.1016/j.ijantimicag.2024.107302_bib0006 – volume: 76 year: 2023 ident: 10.1016/j.ijantimicag.2024.107302_bib0016 article-title: Association between increased linezolid plasma concentrations and the development of severe toxicity in multidrug-resistant tuberculosis treatment publication-title: Clin Infect Dis doi: 10.1093/cid/ciac485 – volume: 78 start-page: 730 year: 2024 ident: 10.1016/j.ijantimicag.2024.107302_bib0005 article-title: The safety and tolerability of linezolid in novel short-course regimens containing bedaquiline, pretomanid, and linezolid to treat rifampicin-resistant tuberculosis: an individual patient data meta-analysis publication-title: Clin Infect Dis doi: 10.1093/cid/ciad653 – volume: 9 start-page: 640 year: 2005 ident: 10.1016/j.ijantimicag.2024.107302_bib0008 article-title: Speaking the same language: treatment outcome definitions for multidrug-resistant tuberculosis publication-title: Int J Tuberc Lung Dis – volume: 15 start-page: 41 year: 2016 ident: 10.1016/j.ijantimicag.2024.107302_bib0002 article-title: Efficacy and safety profile of linezolid in the treatment of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis: a systematic review and meta-analysis publication-title: Ann Clin Microbiol Antimicrob doi: 10.1186/s12941-016-0156-y – volume: 10 start-page: 93 year: 1994 ident: 10.1016/j.ijantimicag.2024.107302_bib0013 article-title: Harmonisation in pharmacovigilance publication-title: Drug Saf doi: 10.2165/00002018-199410020-00001 – year: 2022 ident: 10.1016/j.ijantimicag.2024.107302_bib0007 – volume: 42 start-page: 83 year: 2020 ident: 10.1016/j.ijantimicag.2024.107302_bib0019 article-title: Therapeutic drug monitoring can improve linezolid dosing regimens in current clinical practice: a review of linezolid pharmacokinetics and pharmacodynamics publication-title: Ther Drug Monit doi: 10.1097/FTD.0000000000000710 – volume: 40 start-page: 839 year: 1996 ident: 10.1016/j.ijantimicag.2024.107302_bib0012 article-title: In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.40.4.839 – volume: 7 start-page: 603 year: 2015 ident: 10.1016/j.ijantimicag.2024.107302_bib0001 article-title: Systematic review and meta-analysis of the efficacy and safety of therapy with linezolid containing regimens in the treatment of multidrug-resistant and extensively drug-resistant tuberculosis publication-title: J Thorac Dis – volume: 2 start-page: 1627 year: 2015 ident: 10.1016/j.ijantimicag.2024.107302_bib0014 article-title: Linezolid trough concentrations correlate with mitochondrial toxicity-related adverse events in the treatment of chronic extensively drug-resistant tuberculosis publication-title: EBioMedicine doi: 10.1016/j.ebiom.2015.09.051 – volume: 45 start-page: 161 year: 2015 ident: 10.1016/j.ijantimicag.2024.107302_bib0017 article-title: Efficacy, safety and tolerability of linezolid for the treatment of XDR-TB: a study in China publication-title: Eur Respir J doi: 10.1183/09031936.00035114 – volume: 60 year: 2022 ident: 10.1016/j.ijantimicag.2024.107302_bib0010 article-title: Epidemiological cut-off values for a 96-well broth microdilution plate for high-throughput research antibiotic susceptibility testing of M. tuberculosis publication-title: Eur Respir J – volume: 8 start-page: 383 year: 2020 ident: 10.1016/j.ijantimicag.2024.107302_bib0004 article-title: Drug-associated adverse events in the treatment of multidrug-resistant tuberculosis: an individual patient data meta-analysis publication-title: Lancet Respir Med doi: 10.1016/S2213-2600(20)30047-3 – volume: 77 start-page: 1146 year: 2022 ident: 10.1016/j.ijantimicag.2024.107302_bib0015 article-title: Linezolid toxicity in patients with drug-resistant tuberculosis: a prospective cohort study publication-title: J Antimicrob Chemother doi: 10.1093/jac/dkac019 – volume: 26 start-page: 1792 year: 2020 ident: 10.1016/j.ijantimicag.2024.107302_bib0003 article-title: Linezolid-associated neurologic adverse events in patients with multidrug-resistant tuberculosis publication-title: France. Emerg Infect Dis. doi: 10.3201/eid2608.191499 – year: 2013 ident: 10.1016/j.ijantimicag.2024.107302_bib0009 – volume: 49 start-page: 688 year: 2017 ident: 10.1016/j.ijantimicag.2024.107302_bib0011 article-title: Simple strategy to assess linezolid exposure in patients with multi-drug-resistant and extensively-drug-resistant tuberculosis publication-title: Int J Antimicrob Agents doi: 10.1016/j.ijantimicag.2017.01.017 – volume: 8 start-page: 86 year: 2017 ident: 10.1016/j.ijantimicag.2024.107302_bib0018 article-title: Long-term effects, pathophysiological mechanisms, and risk factors of chemotherapy-induced peripheral neuropathies: a comprehensive literature review publication-title: Front Pharmacol doi: 10.3389/fphar.2017.00086
SSID	ssj0015345
Score	2.462918
Snippet	Linezolid treatment has a high risk of toxicity and adverse drug reactions (ADR) are frequent. Few studies have investigated risk factors of major ADRs... AbstractObjectivesLinezolid treatment has a high risk of toxicity and adverse drug reactions (ADR) are frequent. Few studies have investigated risk factors of... Objectives: Linezolid treatment has a high risk of toxicity and adverse drug reactions (ADR) are frequent. Few studies have investigated risk factors of major...
SourceID	swepub proquest pubmed crossref elsevier
SourceType	Open Access Repository Aggregation Database Index Database Enrichment Source Publisher
StartPage	107302
SubjectTerms	adverse drug reactions Anaemia Drug concentrations Infectious Disease Leukopenia Linezolid MDR-TB Peripheral neuropathy Thrombocytopenia
Title	Increased risk of adverse drug reactions by higher linezolid dose per weight in multidrug-resistant tuberculosis
URI	https://www.clinicalkey.com/#!/content/1-s2.0-S0924857924002188 https://www.clinicalkey.es/playcontent/1-s2.0-S0924857924002188 https://dx.doi.org/10.1016/j.ijantimicag.2024.107302 https://www.ncbi.nlm.nih.gov/pubmed/39146999 https://www.proquest.com/docview/3093594877 https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-207970
Volume	64
WOSCitedRecordID	wos001309786300001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText	1
inHoldings	1
isFullTextHit
isPrint
journalDatabaseRights	– providerCode: PRVESC databaseName: Elsevier SD Freedom Collection Journals 2021 customDbUrl: eissn: 1872-7913 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0015345 issn: 0924-8579 databaseCode: AIEXJ dateStart: 20170901 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwELf2AYgXBINB-Zg8Ce2ly-Qkbe0gXirYBJMYkxiob5ZjO21GSaqmHSv_EP8m5zhxCtukIsRLVNm5us394juff75D6CX4DGGSyMQLRE96nSAOPcFi6gU6Il1JFFhAUhaboCcnbDCITtfWftZnYS7GNMvY5WU0-a-qhjZQtjk6-xfqdl8KDfAZlA5XUDtcV1I8vPGGaK4b2rgwRZcL3VbT-bANfdKy38DxHFmWh3E1f-TjVLWVoa9PoOl7GTI10ZCScmhEPViZG28zm7Vn81hP5XycF2mx7N7-Hl9cykoBQum3tEz6ZJITDOsMUnYXaVRVjT_ORyLLnKEwfHtdtI_yaVEfkUib3o91Y98UkHaRoq8mKUdNWvsghoYwXQlVwY2g42hyVcStPnXTUJzK0CXcyLq2CE09i9tc6BVaO9caBxunOD9Iz6s_LYYHZlDogXkuaCyi4yl-MkOZkQzTFpwhto42A9qNYPrc7L8_HBy7DatuWNbDdj_tDtptqIQ3DHiTK3R1qfNHHtvS9zm7j-5Vixbct2B7gNZ0toVu2zKmiy20d2rzny_28VlznK_Yx3v4tMmMvniIJg6b2GAT5wmusIkNwLDDJo4X2GITO2xig00M2MQWmzjN8DXYxMvYfIQ-Hx2evXnnVSU_PAmu9MxLFFGCSD8JophG0idEUyGVMLVpVaKZVLob01CThCShVDJgiRCM9ETYY77wabiNNrI8008QVpL14HawT13VibWp3OBLDe4X9SOhNGkhVj99Lqt8-KYsy5jXxMdzvqQ4bhTHreJaKHCiE5sUZhWhV7WKeX3qGew0B3SuIkyvE9ZF9SYX3OdFwAm_gtgWeu0kK6faOsurDrxbo5GD4TG7iSLT-bzgJYUi6jBKW-ixhal7GGEEDhgsPVtoz-LW9Zhs9m_TL32eT4d8nM5hLBpR8vRfHs4zdLeZO56jjdl0rl-gW_JilhbTHbROB2ynel9_AUrPJHY
linkProvider	Elsevier
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Increased+risk+of+adverse+drug+reactions+by+higher+linezolid+dose+per+weight+in+multidrug-resistant+tuberculosis&rft.jtitle=International+journal+of+antimicrobial+agents&rft.au=Kuhlin%2C+Johanna&rft.au=Davies+Forsman%2C+Lina&rft.au=Osman%2C+Aisha&rft.au=Skagerberg%2C+Magdalena&rft.date=2024-10-01&rft.pub=Elsevier+Ltd&rft.issn=0924-8579&rft.volume=64&rft.issue=4&rft_id=info:doi/10.1016%2Fj.ijantimicag.2024.107302&rft.externalDocID=S0924857924002188
thumbnail_m	http://cvtisr.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F09248579%2Fcov200h.gif